Rose is a managing editor at The American Journal of Managed Care® (AJMC®).
She has a BA in journalism & media studies and Spanish from Rutgers University. You can connect with Rose on LinkedIn.
Despite Treatment Improvements, Second Primary Malignancies Adversely Affect MM Prognosis
September 20th 2023In a real-world study using data from patients diagnosed with multiple myeloma between 2009 and 2021, second primary malignancies adversely impacted survival outcomes in the modern era of therapeutics.
Read More
Novel PET-Based Radiomics Signature Predicts CAR T Efficacy in DLBCL
September 15th 2023A PET-based radiomics signature was able to predict the efficacy of chimeric antigen receptor (CAR) T-cell therapy and performed better than conventional PET biomarkers in patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
Read More
Long-Term Data Show Consistent OS Benefit With Nivolumab Plus Ipilimumab in mNSCLC
September 13th 2023The combination demonstrated durable survival benefits among patients with metastatic non–small cell lung cancer (mNSCLC) regardless of PD-L1 expression levels at a minimum follow-up of more than 6 years.
Read More
AML-Specific Early Mortality Risk Indices May Increase Accuracy of Care Quality Measurements
September 8th 2023A study found acute myeloid leukemia (AML) salvage therapy was independently associated with early mortality compared with frontline therapy, suggesting that algorithms measuring quality of care should incorporate risk mortality indices that factor in disease characteristics and treatment status.
Read More
National Alliance Guideline Identifies Key PBM Concerns for Health Plan Purchasers
September 7th 2023The playbook includes resources for purchasers to help in their dealings with pharmacy benefit managers (PBMs), including best practice checklists, sample questionnaires for choosing consultants, and recommendations for contracting language.
Read More
Review Highlights Knowledge Gaps in Lymphoma Treatment Outcomes in AYAs
September 7th 2023The review summarized existing evidence around short- and long-term treatment-related toxicities among adolescents and young adults (AYAs), as well as gaps in care guidelines for AYA survivors of lymphoma.
Read More
Dr Sachin Jain on the Changing Doctor-Patient Relationship and Middlemen in Health Care
September 1st 2023Sachin Jain, MD, MBA, president and CEO at SCAN Group and SCAN Health Plan, discussed the growing roles of middlemen between physicians and their patients in an increasingly complex system.
Read More
Study Suggests CAR T-Cell Therapy Safe, Effective After Allo-SCT in Multiple Myeloma
August 26th 2023A retrospective analysis of the CARTITUDE-1 trial suggests that patients who have undergone allogeneic stem cell transplant (allo-SCT) prior to receiving chimeric antigen receptor (CAR) T-cell therapy for multiple myeloma experience comparable outcomes to allo-SCT–naïve patients.
Read More
Dr Jennifer Brown Discusses Zanubrutinib Uptake in CLL, SLL
August 23rd 2023Jennifer Brown, MD, PhD, director of the Chronic Lymphocytic Leukemia Center at Dana-Farber Cancer Institute, discussed the uptake of zanubrutinib for the treatment of chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia (SLL).
Read More
EMA Accepts Marketing Application for Odronextamab in R/R DLBCL, Follicular Lymphoma
August 18th 2023The European Medicines Agency (EMA) has accepted a Marketing Authorization Application (MAA) for odronextamab for relapsed/refractory (R/R) follicular lymphoma (FL) or R/R diffuse large B-cell lymphoma (DLBCL) following disease progression after at least 2 prior lines of systemic therapy.
Read More
CAR T-Cell Therapy Shown Safe, Effective in MCL With CNS Involvement
August 18th 2023A small study suggests the use of anti-CD19 chimeric antigen receptor (CAR) T-cell therapy in patients with mantle cell lymphoma (MCL) with secondary central nervous system (CNS) involvement is safe and effective.
Read More
Axi-Cel Extends Survival vs Standard of Care for R/R LBCL
August 11th 2023An overall survival (OS analysis of the phase 3 ZUMA-7 trial demonstrated longer OS in patients treated with axicabtagene ciloleucel (axi-cel) vs the standard of care for early relapsed or refractory (R/R) large B-cell lymphoma (LBCL).
Read More
Atorvastatin May Mitigate Risk of Cardiac Events Due to Anthracycline Use in Lymphoma
August 10th 2023Anthracyclines are widely used to treat hematological and solid-tumor cancers, but past research suggests their use may be associated with late cardiac effects, including heart failure, among patients with lymphomas and other cancers.
Read More
Coverage of sessions on disparities in access to clinical trials and cancer screening, as well as relationships each to outcomes. A joint session presented by ASCO and the European Society for Medical Oncology (ESMO) highlighted progress and lingering gaps in lung and colorectal screening.
Read More
ASCO 2023: Leukemia and Lymphoma
July 31st 2023Results include a landmark study that involved seamless collaboration across adult and pediatric patient groups, leading to a highly diverse study population. Other coverage addresses access to novel therapies and what's coming in the pipeline, including CAR T-cell therapy with tyrosine kinase inhibitors.
Read More
Patients With CML Feel Shared Decision-Making Is Lacking, Want More Focus on QOL
July 25th 2023Data from the Survey of Unmet Needs in Chronic Myeloid Leukemia (CML SUN) trial show that quality of life (QOL) and shared decision-making are priorities for patients, said Fabian Lang, MD, of Goethe University Hospital in Frankfurt, Germany.
Read More
Higher Spleen Volume at HSCT Associated With Worse Outcomes in AML
July 21st 2023A recent study found that higher spleen volume before undergoing allogeneic hematopoietic stem cell transplantation (HSCT) was associated with worse overall survival and higher nonrelapse mortality incidence in patients with acute myeloid leukemia (AML).
Read More
Dr Wojciech Jurczak Discusses Changing Treatment Options for R/R DLBCL
July 20th 2023Wojciech Jurczak, MD, PhD, head of the Department of Oncology at Maria Sklodowska-Curie National Research Institute of Oncology, discusses the changing therapy landscape for relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
Read More
Common CVD Biomarkers May Hold Prognostic Value in MDS, Study Finds
July 19th 2023The findings suggest that circulating N-terminal pro-B-type natriuretic peptide and growth differentiation factor-15, both soluble biomarkers of cardiovascular disease (CVD), may be indicators of the course of myelodysplastic syndromes (MDS) and outcomes.
Read More
ePROM Monitoring of Patients With Inflammatory Arthritides May Be Beneficial, Review Suggests
July 15th 2023Utilizing electronic patient-reported outcome measures (ePROMs) may hold potential to reduce health care resource utilization without affecting outcomes for patients with inflammatory arthritides, such as rheumatoid arthritis.
Read More
Study Explores Risk Factors for Therapy-Related MDS, AML Following HCT for Multiple Myeloma
July 14th 2023The occurrence of treatment-related myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) after autologous hematopoietic cell transplantation (HCT) for multiple myeloma was associated with aggressive disease characteristics and poor outcomes.
Read More